131933-60-3

Basic information

• Product Name: rac-1-eicosanamido-2-ethoxy-3-(trityloxy)propane
• Synonyms: rac-1-eicosanamido-2-ethoxy-3-(trityloxy)propane
• CAS NO: 131933-60-3
• Molecular Weight: 656.005
• Mol File: 131933-60-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: rac-1-eicosanamido-2-ethoxy-3-(trityloxy)propane(CAS DataBase Reference)
• NIST Chemistry Reference: rac-1-eicosanamido-2-ethoxy-3-(trityloxy)propane(131933-60-3)
• EPA Substance Registry System: rac-1-eicosanamido-2-ethoxy-3-(trityloxy)propane(131933-60-3)

Safety Data

• Hazardous Substances Data: 131933-60-3(Hazardous Substances Data)

Upstream product

• 131973-32-5 rac-1-O-tosyl-2-O-ethylglycerol 
• 74-96-4 ethyl bromide 
• 506-30-9 Arachidic acid 
• 131933-50-1 rac-1-amino-2-ethoxy-3-(trityloxy)propane 
• 22598-16-9 2-ethoxy-propane-1,3-diol 

Downstream Products

• 149576-20-5 rac-3-eicosanamido-2-ethoxypropylphosphocholine 

Relevant articles and documents

Structure-activity relationship for enhancement of paracellular permeability across Caco-2 cell monolayers by 3-alkylamido-2-alkoxypropylphosphocholines

Paracellular permeability enhancers have been used to improve the oral bioavailability of hydrophilic drugs; however, the mechanism of action of many enhancers is poorly understood. In this study, highly potent enhancers of paracellular permeability were

In Vitro Evaluation of Phosphocholine and Quaternary Ammonium Containing Lipids as Novel Anti-HIV Agents

A series of synthetic lipids containing a two- or three-carbon backbone substituted with a thio, oxy, or amidoalkyl functionality and either a phosphocholine or quaternary ammonium moiety was evaluated as potential anti-HIV-1 agents.Several analogues were identified as possessing activity with the most promising compound being rac-3-octadecanamido-2-ethoxypropylphosphocholine (8).Compound 8 exhibited an IC50 for the inhibition of plaque formation of 0.16 μM wich was 84-fold lower than the IC50 value determined for CEM-SS cell growth inhibition.Initial mechanistic studies have indicated that these compounds, unlike AZT, are not reverse transcriptase (RT) inhibitors, but instead appear to inhibit a late step in HIV replication involving virus assembly and infectious virus production.Since these lipids are acting via a different mechanism, they represent an alternative approach to the chemotherapeutic treatment of AIDS as well as candidates for combination therapy with AZT.